Sarepta shares positive safety update on DM1 asset as Arrowhead snares $200M milestone
A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study also hitting an enrollment target, triggering a $200 milestone payment due…